Wall Street brokerages predict that Teladoc (NYSE:TDOC) will post ($0.35) earnings per share for the current fiscal quarter, Zacks reports. Ten analysts have provided estimates for Teladoc’s earnings, with the lowest EPS estimate coming in at ($0.37) and the highest estimate coming in at ($0.33). Teladoc posted earnings of ($0.28) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 25%. The business is scheduled to issue its next earnings report on Wednesday, August 1st.
According to Zacks, analysts expect that Teladoc will report full-year earnings of ($1.37) per share for the current financial year, with EPS estimates ranging from ($1.43) to ($1.31). For the next year, analysts forecast that the firm will post earnings of ($0.87) per share, with EPS estimates ranging from ($1.16) to ($0.41). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that follow Teladoc.
Teladoc (NYSE:TDOC) last posted its quarterly earnings data on Tuesday, May 1st. The health services provider reported ($0.39) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.04. Teladoc had a negative net margin of 41.06% and a negative return on equity of 20.40%. The company had revenue of $89.64 million for the quarter, compared to the consensus estimate of $86.77 million. During the same period last year, the company earned ($0.30) earnings per share. The firm’s revenue was up 109.0% compared to the same quarter last year.
Several equities analysts recently weighed in on the stock. Craig Hallum set a $39.00 target price on shares of Teladoc and gave the company a “hold” rating in a research note on Wednesday, May 2nd. Jefferies Group assumed coverage on shares of Teladoc in a research note on Friday, January 26th. They issued a “buy” rating and a $40.00 target price for the company. Deutsche Bank cut shares of Teladoc from a “buy” rating to a “hold” rating and set a $45.00 target price for the company. in a research note on Thursday, March 15th. Canaccord Genuity raised their target price on shares of Teladoc from $43.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, February 28th. Finally, ValuEngine raised shares of Teladoc from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $42.67.
In other Teladoc news, VP Mark Hirschhorn sold 69,460 shares of Teladoc stock in a transaction on Wednesday, May 2nd. The shares were sold at an average price of $43.73, for a total transaction of $3,037,485.80. Following the completion of the transaction, the vice president now directly owns 50,042 shares of the company’s stock, valued at $2,188,336.66. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Jason N. Gorevic sold 25,000 shares of Teladoc stock in a transaction on Tuesday, May 15th. The stock was sold at an average price of $48.93, for a total transaction of $1,223,250.00. Following the transaction, the chief executive officer now directly owns 636,184 shares of the company’s stock, valued at $31,128,483.12. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 483,954 shares of company stock valued at $19,960,682. Company insiders own 3.95% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new stake in shares of Teladoc during the fourth quarter worth $101,000. We Are One Seven LLC lifted its holdings in shares of Teladoc by 241.1% during the first quarter. We Are One Seven LLC now owns 2,845 shares of the health services provider’s stock worth $115,000 after buying an additional 2,011 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Teladoc by 68.8% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,874 shares of the health services provider’s stock worth $116,000 after buying an additional 1,171 shares in the last quarter. Rockefeller Capital Management L.P. acquired a new stake in shares of Teladoc during the first quarter worth $154,000. Finally, Montag A & Associates Inc. acquired a new stake in shares of Teladoc during the fourth quarter worth $200,000.
Shares of Teladoc traded up $0.55, hitting $49.90, during midday trading on Monday, Marketbeat reports. The stock had a trading volume of 595,978 shares, compared to its average volume of 1,055,105. Teladoc has a 12 month low of $27.30 and a 12 month high of $50.60. The company has a current ratio of 4.15, a quick ratio of 4.15 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $3.08 billion, a PE ratio of -30.24 and a beta of 0.35.
Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.